We have been made aware of a temporary product name change as a result of a supplier (Scope Ophthalmics Ltd) rebranding VitA-POS eye ointment to Hylo Night eye ointment for a short period of time during 2020, before reverting the name to VitA-POS eye ointment. There are no changes to the product formulation. The change of product name may affect your practice prior to the deployment of the June 2020 Gemscript release
Dm+d had classed this as a name change in early April, with VitA-POS eye ointment becoming Hylo Night eye ointment.
However in early May they changed this by reverting the name to VitA-POS eye ointment and adding Hylo Night eye ointment as a new product.
Unfortunately these changes span across two Gemscript releases, April and May 2020.
- Pre-deployment of the May 2020 Gemscript release, the product is listed as VitA-POS eye ointment
- Post-deployment of the May 2020 Gemscript release but pre-deployment of the June 2020 Gemscript release, the product is listed as Hylo Night eye ointment (changed from VitA-POS eye ointment). Patients with an existing repeat prescription for VitA-POS eye ointment will have these changed to Hylo Night eye ointment.
- Post-deployment of the June 2020 Gemscript release, the product name is reverted to VitA-POS eye ointment and Hylo Night eye ointment will also be listed as available to prescribe.
Note - Patients with an existing repeat for VitA-POS eye ointment will have them changed to Hylo Night eye ointment with May’s update, they will then automatically revert to VitA-POS eye ointment with June’s update.